Stock Performance and Market Context
On 24 Feb 2026, Unichem Laboratories Ltd’s stock price reached Rs.350.45, the lowest level in the past year. This decline comes after two consecutive days of losses, with the stock falling by 4.43% over this period. The day’s performance saw a further dip of 1.14%, underperforming the Pharmaceuticals & Biotechnology sector by 0.84%. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In comparison, the Sensex index also experienced a decline, falling 522.35 points or 0.92% to close at 82,530.19. Despite this, the Sensex remains 4.4% below its 52-week high of 86,159.02, with its 50-day moving average still positioned above the 200-day moving average, indicating a more resilient broader market backdrop.
Over the last year, Unichem Laboratories Ltd’s stock has delivered a negative return of 45.89%, contrasting sharply with the Sensex’s positive 10.85% gain. The stock’s 52-week high was Rs.727.95, highlighting the extent of the recent decline.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Metrics and Profitability Analysis
Unichem Laboratories Ltd’s financial profile reveals several areas of concern that have contributed to the stock’s subdued performance. The company’s Debt to EBITDA ratio stands at 4.87 times, indicating a relatively high leverage level and a constrained ability to service debt obligations efficiently. This metric is a critical factor for investors assessing financial stability and risk exposure.
Long-term growth has been modest, with net sales increasing at an annualised rate of 11.95% over the past five years. However, profitability metrics remain underwhelming. The average Return on Equity (ROE) is 1.44%, reflecting limited profitability generated per unit of shareholders’ funds. This low ROE suggests challenges in translating sales growth into meaningful earnings for shareholders.
Recent quarterly results for the period ending December 2025 further illustrate these pressures. Profit Before Tax (PBT) excluding other income declined sharply by 77.2% to Rs.6.11 crore compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) fell by 56.0% to Rs.16.13 crore over the same period. Meanwhile, interest expenses for the latest six months increased by 30.50% to Rs.15.66 crore, adding to the financial strain.
Long-Term and Short-Term Performance Trends
The stock’s underperformance extends beyond the recent quarter. Over the past three years, one year, and three months, Unichem Laboratories Ltd has consistently lagged behind the BSE500 index. This persistent underperformance highlights structural challenges in the company’s growth and earnings trajectory.
Despite these setbacks, the company has demonstrated healthy long-term growth in operating profit, which has expanded at an annual rate of 148.09%. This growth in operating profit contrasts with the subdued net sales growth and suggests some operational efficiencies or cost management improvements.
Return on Capital Employed (ROCE) is recorded at 4.9%, which, while modest, supports a valuation that is considered very attractive. The company’s Enterprise Value to Capital Employed ratio stands at 1, indicating that the stock is trading at a discount relative to its capital base. This valuation is lower than the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector.
Considering Unichem Laboratories Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Profitability and Valuation Metrics
Over the past year, while the stock price has declined by 45.89%, the company’s profits have increased by 29.9%. This divergence is reflected in the Price/Earnings to Growth (PEG) ratio of 0.8, which suggests that the stock is trading at a valuation that is not fully aligned with its profit growth. Such a PEG ratio typically indicates a stock priced attractively relative to earnings growth, although other financial and market factors have weighed on the share price.
The majority shareholding remains with the promoters, which can be a stabilising factor in governance and strategic direction. However, the combination of high debt levels, rising interest costs, and subdued returns on equity continues to influence market sentiment.
Summary of Key Financial Indicators
To summarise, Unichem Laboratories Ltd’s key financial indicators as of early 2026 are as follows:
- Debt to EBITDA ratio: 4.87 times
- Net sales growth (5-year CAGR): 11.95%
- Return on Equity (average): 1.44%
- Operating profit growth (annualised): 148.09%
- Return on Capital Employed: 4.9%
- Enterprise Value to Capital Employed: 1
- PEG ratio: 0.8
- Interest expense growth (latest six months): 30.50%
These metrics provide a comprehensive view of the company’s financial health and valuation context amid the recent stock price decline.
Market and Sector Positioning
Within the Pharmaceuticals & Biotechnology sector, Unichem Laboratories Ltd’s Mojo Score is 31.0, with a Mojo Grade of Sell as of 16 Feb 2026. This represents an upgrade from a previous Strong Sell rating, indicating some improvement in the company’s outlook, albeit still below investment-grade thresholds. The Market Cap Grade is 3, reflecting a mid-tier market capitalisation relative to peers.
The stock’s recent underperformance relative to the sector and broader market indices underscores the challenges faced by the company in maintaining competitive positioning and delivering shareholder returns.
Conclusion
Unichem Laboratories Ltd’s stock reaching a 52-week low of Rs.350.45 highlights a period of subdued market performance influenced by financial leverage, profitability constraints, and recent quarterly earnings declines. While certain valuation metrics suggest the stock is trading at a discount relative to capital employed and profit growth, the overall financial profile and market trends have contributed to the current price level. The company’s position within the Pharmaceuticals & Biotechnology sector and its recent rating upgrade reflect a nuanced outlook amid ongoing market pressures.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
